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Abstract
T cell trafficking at vascular sites has emerged as a key step in antitumor immunity. Chemokines 
are credited with guiding the multistep recruitment of CD8+ T cells across tumor vessels. 
However, the multiplicity of chemokines within tumors has obscured the contributions of 
individual chemokine receptor/chemokine pairs to this process. Moreover, recent studies have 
challenged whether T cells require chemokine receptor signaling at effector sites. Here, we 
investigate the hierarchy of chemokine receptor requirements during T cell trafficking to murine 
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and human melanoma. These studies reveal a non-redundant role for GαI-coupled CXCR3 in 
stabilizing intravascular adhesion and extravasation of adoptively transferred CD8+ effectors that 
is indispensable for therapeutic efficacy. In contrast, functional CCR2 and CCR5 on CD8+ 
effectors fail to support trafficking despite the presence of intratumoral cognate chemokines. 
Taken together, these studies identify CXCR3-mediated trafficking at the tumor vascular interface 
as a critical checkpoint to effective T cell-based cancer immunotherapy.
Introduction
The immune contexture is widely recognized as an important determinant of overall survival 
in cancer patients1. In particular, the presence of cytotoxic CD8+ T cells at high density 
within tumor tissue is beneficial in multiple cancer types including colorectal, ovarian, and 
melanoma, and can be a better prognostic indicator of patient outcome than traditional 
tumor-node-metastasis (TMN) staging1–6. Active areas of research seek to improve T cell-
mediated immunity in patients by focusing on therapeutics that manipulate either the T cell 
arm of antitumor immunity or the tumor microenvironment where T cells execute their 
effector functions7–9. The frequency of tumor-specific T cells and their cytotoxic function 
can be boosted through DC vaccination, adoptive T cell transfer (ACT) therapy, or 
administration of checkpoint blockade inhibitors (e.g., targeting immunosuppressive 
molecules such as cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] or programmed-
death/programmed-death ligand 1 [PD-1/PD-L1]) and has led to durable responses in a 
subset of patients8,10–13. Alternatively, we and others have converted the tumor 
microenvironment from relatively ‘low’ to ‘high’ sites of T cell infiltration in preclinical 
studies using TLR agonists, IFNs, antagonists of endothelin B and angiogenic factors, or 
interleukin-6 (IL-6)-dependent strategies9,14–17. Fundamental to the efficacy of all T cell-
based immunotherapy is the requirement for blood-borne T cells to gain entry across tumor 
vascular gateways in order to engage in contact-dependent lysis of neoplastic targets.
Given the importance of intratumoral localization of T cells for antitumor immunity, there is 
surprisingly little known about the trafficking cues necessary to direct extravasation of 
effector T cells across tumor vessels. Chemokines are considered strong candidates for this 
process based on their well-established role in T cell trafficking to lymphoid organs18. In 
lymph nodes, for example, the interaction between Gαi-protein-coupled chemokine receptors 
(e.g., CCR7) on naïve T cells and chemokine (CCL21) displayed on the lumenal surface of 
blood vessels is an obligate step for triggering LFA-1–dependent stable adhesion and 
subsequent transendothelial migration18,19. Insight into the role of chemokines in the tumor 
microenvironment stems from correlative studies linking T cell accumulation with multiple 
chemokine receptors on effector T cells and/or chemokines within the tumor locale1,20,21. In 
this regard, expression of CXCR3 on circulating T cells or its chemokine ligands, CXCL9 
and CXCL10, in tumor tissues is associated with elevated intratumoral T cell infiltration and 
a favorable outcome in melanoma and colorectal cancer patients1,20–22. Similar clinical 
evidence connects CCR5 and its ligands (CCL3, CCL4, and CCL5), as well as CCR2 and its 
ligand CCL2, to intratumoral T cell infiltration and disease-free survival1,20,21. These 
observations are suggestive of redundant functions by chemokine receptors during T cell 
homing into tumors although chemokines could alternatively orchestrate T cell activities 
Mikucki et al. Page 2
Nat Commun. Author manuscript; available in PMC 2015 December 25.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
within the tumor interstitium (e.g., proliferation, survival, retention, or egress)19. Moreover, 
the prototypical role for chemokines has recently been challenged by reports in non-
tumorigenic inflammatory settings that CD8+ effector T cells with high LFA-1 expression 
bypass chemokine requirements for stable adhesion within vessels23,24. Thus, in the absence 
of a head-to-head comparison of the chemokine receptor usage at the tumor vascular 
interface, it remains unclear whether chemokines are operative during T cell entry into 
tumors or if there is any preferential role for individual chemokine receptors/chemokine 
pairs during extravasation.
Here, we investigated the hierarchy of chemokine receptor requirements during T cell 
trafficking by tracking the fate of adoptively transferred CD8+ effector T cells in murine and 
human melanoma tumors. We compared the functions of three chemokine receptors 
previously implicated in intratumoral CD8+ effector T cell infiltration (i.e., CXCR3, CCR5, 
and CCR2) in tumors expressing complementary chemokine ligands. These studies 
unexpectedly reveal a non-redundant requirement for the CXCR3-CXCL9/CXCL10 axis for 
CD8+ T cell trafficking within the intravascular space that could not be predicted from static 
profiling of intratumoral chemokines or their receptors on T cells. We further establish a 
causal link between CXCR3-dependent trafficking and the efficacy of adoptive T cell 
transfer therapy. These findings identify CXCR3 interactions with cognate chemokines 
within the vessel wall as a critical checkpoint dictating the efficacy of T cell-based cancer 
immunotherapy.
Results
Tumor microenvironment enriched for T cell chemoattractants
To address the chemokine receptor requirements during T cell homing, we first 
characterized the chemokine milieu in highly aggressive, orthotopic B16 murine melanoma 
expressing the surrogate tumor antigen ovalbumin (OVA)14. For these studies, we focused 
on inflammatory chemokines previously implicated in T cell infiltration in patient 
tumors1,3,9,20. High concentrations (~1 ng per mg total protein) of CXCL9, CXCL10 (i.e., 
the two CXCR3 ligands expressed in the C57BL/6 strain25), CCL5 (CCR5 ligand), and 
CCL2 (CCR2 ligand) were detected in B16-OVA tumor extracts compared to non-inflamed 
normal skin following subcutaneous injection of PBS (Fig. 1a).
Complementary studies profiled CD8+ effector T cells for functional receptors specific for 
the inflammatory chemokines found in the tumor microenvironment. Chemotactic activity 
was tested in vitro for CD8+ T cells from OVA-specific OT-I transgenic mice [wild-type 
(WT)] or chemokine receptor-deficient mice that were activated ex vivo to simulate the 
expansion of T cells for clinical ACT immunotherapy12,14,26. WT OT-I effector populations 
(>96% CD8+CD44hi, Supplementary Fig. 1a) exhibited strong migration to recombinant 
CXCL9, CXCL10, CCL5, and CCL2, that was blocked by pertussis toxin (PTX), a global 
inhibitor of Gαi protein-coupled chemokine receptor signaling (Fig. 1b). Genetic deletion of 
Cxcr3 (crossed on an OT-I background; Cxcr3−/− OT-I) or Ccr5 and Ccr2 (on a C57BL/6 
background) was further shown to specifically block T cell migration to its cognate ligands 
without impairing the response to other ligands (Fig. 1b). CD8+ CD44hi T cells activated ex 
vivo exhibited a CXCR3hi CCR2int/lo CCR5int/lo phenotype which was also typical of CD8+ 
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T cells activated in vivo (i.e., detected in draining nodes following DC vaccination or tumor 
implantation; Supplementary Fig. 1b). Collectively, these data indicate that CD8+ effector T 
cells express a repertoire of functional chemokine receptors which would be expected to 
guide trafficking to chemokine-rich tumors in situ.
CXCR3 signaling obligate for intratumoral T cell trafficking
Short-term (1 hour) competitive homing assays were used14,27 to determine whether Gαi-
chemokine signaling was obligatory for T cell trafficking in B16-OVA. In these assays, WT 
effector OT-I cells were admixed at a 1:1 ratio with PTX-pretreated WT OT-I T cells 
(labeled with different tracking dyes) prior to intravenous ACT (Fig. 2a). After 1 hour, the 
ratio of T cells was determined in tumor tissues by flow cytometry, and data are reported for 
homing relative to untreated WT OT-I cells. This 1 hour time-frame enabled us to 
discriminate chemokine functions specifically at the vessel wall since it is sufficient for cells 
to complete steps leading to extravasation14, but not long enough for other processes to 
occur that influence the extent of T cell infiltration (i.e., proliferation in situ, survival, 
retention and egress). Homing of PTX-treated OT-I was less efficient than WT OT-I, as 
indicated by the 1:3 ratio of PTX:WT cells recovered in tumors (Fig. 2b). This was in 
contrast to control experiments where a 1:1 ratio of intratumoral WT:WT cells was detected. 
Access of effector T cells to the spleen via the peripheral circulation was not affected by 
functional chemokine receptor status (Fig. 2b). These data establish that Gαi-coupled 
chemokine receptor signaling is necessary for effector CD8+ T cell homing in tumors.
We next investigated whether there was a hierarchy of chemokine receptor usage during 
extravasation into tumor tissue. Initial studies focused on CXCR3 requirements for the entry 
of adoptively transferred effector T cells in competitive (1 hour) homing assays in which 
WT OT-I cells were admixed with Cxcr3−/− OT-I T cells or with OT-I cells pre-treated with 
a CXCR3-blocking antibody (Ab). Surprisingly, despite expression of functional CCR5 and 
CCR2 (Fig. 1b), loss of the single chemokine receptor, CXCR3, reduced T cell trafficking to 
the same extent as global blockade of chemokine signaling by PTX (Fig. 2b). Further head-
to-head comparison of admixed PTX-pretreated and Cxcr3−/− OT-I cells in the same 
recipient mice substantiated that CXCR3 accounted for all Gαi-coupled chemokine receptor-
dependent trafficking by CD8+ effectors in B16-OVA melanoma (Supplementary Fig. 2a). 
Microscopic quantification of homed cells within the interstitium (i.e., T cells located 
outside CD31+ vessels in tumor sections) further demonstrated an absolute requirement for 
CXCR3 during T cell extravasation (Fig. 2c). Contributions of other chemokine receptors 
failed to emerge even when the overall rate of trafficking was improved (~2 fold) using an 
IL-6–dependent thermal preconditioning strategy (core body temperature elevated to 39.5 ± 
0.5°C, 6 h) that targets the tumor vasculature to be more permissive for T cell homing14 
(Fig. 2d and Supplementary Fig. 2b). CXCR3 dependency was also evident during 
endogenous CD8+ T cell infiltration in tumors implanted in WT mice and Cxcr3-deficient 
mice (Supplementary Fig. 2c), suggesting that the same CXCR3 bias exists whether T cells 
are activated ex vivo or in vivo. Collectively, these data establish a non-redundant role for 
CXCR3-mediated Gαi protein signaling during emigration of blood-borne CD8+ effector T 
cells in the tumor microenvironment.
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CXCR3 ligands mediate T cell firm arrest in tumor vessels
Our findings demonstrated that CXCR3 is required at some point during the multistep 
migration process leading to CD8+ effector T cell migration. These observations prompted 
our use of epifluorescence intravital microscopy to examine whether CXCR3 plays a 
prototypical role in triggering T cell adhesion18,19 within the intravascular space in tumor 
tissues. Since our prior studies established that the frequency of baseline adhesive 
interactions between effector T cell and tumor vessels is near the lower limit of detection by 
live imaging14, we administered thermal therapy to augment homing in order to interrogate 
subtle chemokine requirements. PTX-uncoupling of Gαi protein signaling or genetic deletion 
of Cxcr3 had no impact on the ability of OT-I cells to initiate rolling interactions within 
tumor vessels but strongly inhibited the transition to firm arrest (Fig. 3a). Notably, WT and 
Cxcr3−/− effector OT-I expressed comparable levels of adhesion molecules necessary for 
rolling and firm arrest (i.e., E/P-selectin ligands and CD11a [the α subunit of LFA-1], 
respectively; Supplementary Fig. 3a). The dependence on Gαi protein signaling further was 
not unique to tumor vessels since PTX-pretreated OT-I effectors exhibited significantly 
reduced firm arrest of CD8+ effectors in inflamed skin vessels of non-tumor-bearing mice 
stimulated with the TLR4 agonist, LPS (Supplementary Fig. 3b).
To determine if there was a preferential contribution for individual CXCR3 ligands for 
trafficking, we adapted an approach described previously to visualize membrane-anchored 
adhesion molecules in lymph node vasculature28 in order to determine which CXCR3 
ligands were available in the intravascular space. In the present study, intravascular 
chemokines were quantified microscopically in tissue sections following intravenous 
injection of fluorescent beads conjugated with CXCR3 ligand-specific Ab. These studies 
focused on CXCL9 and CXCL10 since C57BL/6 mice do not express CXCL1125,29. Both 
CXCL9 and CXCL10 were displayed within tumor vessel walls as indicated by specific 
accumulation of α-CXCL10 and α-CXCL9 Ab-conjugated beads in CD31+ vessels 
compared to isotype controls (Fig. 3b), whereas CXCR3 ligand-conjugated beads were not 
evident in normal tissues (e.g., pancreas). We then employed a chemokine blocking strategy 
in which tumor-bearing mice were pre-treated with blocking Ab to CXCL9, CXCL10, or 
combined CXCL9/CXCL1025,30 prior to adoptive transfer of admixed WT:Cxcr3−/− T cells 
(Fig. 3c). Partial inhibition of CD8+ T cell homing was observed with single chemokine 
blockade whereas complete inhibition occurred upon dual targeting of CXCL9 and CXCL10 
(i.e., as indicated by 1:1 ratio of WT:Cxcr3−/− cells recovered at tumor sites following dual 
Ab blockade which was equivalent to the input ratio; Fig. 3c). There was no change in the 
spleen, confirming that the inhibitory effects on intratumoral homing cannot be attributed to 
Ab-mediated T cell clearance. Taken together, these data identify CXCR3 interactions with 
intravascular ligands as a critical step leading to stable adhesion and subsequent 
transendothelial migration of adoptively transferred CD8+ effector T cells at tumor sites.
CCR5 and CCR2 are dispensable for T cell homing to tumors
Results that CCR5 and CCR2 were unable to compensate for loss of CXCR3 in vivo do not 
exclude the possibility that these chemokine receptors cooperate with CXCR3 to control 
adhesion in tumor vessels. There is already precedent for cooperativity involving these 
chemokine receptors31,32. For example, physical interactions between CCR5 and CXCR4 
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are required for CXCR4-mediated enhancement of T cell activation in vitro 32 while 
simultaneous exposure of cells to CCL2 and CCL5 lowers the threshold for downstream 
calcium mobilization31.
To assess whether CCR5 or CCR2 were operative in the context of CXCR3-dependent T 
cell trafficking, we first established that CCL5 and CCL2 were also available in the tumor 
intravascular space, as would be necessary to coordinate with CXCR3 ligands during 
extravasation (Fig. 4a). We then performed competitive homing studies to examine the 
ability of Cxcr3−/−, Ccr5−/−, or Ccr2−/− CD8+ effector CD8+ T cells to traffic compared to 
WT (Fig. 4b). In these experiments the T cells used to track homing were from normal 
C57BL/6 mice, not the OT-I background. Consistent with our results for OT-I cells, 
trafficking was markedly inhibited by PTX-treatment of WT cells or Cxcr3 deficiency, 
indicating that recognition of cognate tumor-associated antigen is not necessary for CXCR3-
dependent T cell extravasation at tumor loci. Conversely, loss of Ccr2 or Ccr5 did not 
compromise T cell entry into B16-OVA tumors or in peripheral sites such as the spleen (Fig. 
4b). Of note, while CCR2 did not contribute to T cell trafficking, there was sufficient ligand 
available to support CCR2-dependent intratumoral recruitment of CD115+ inflammatory 
monocytes33 that have high CCR2 expression relative to CD8+ effectors (Fig. 4c and 4d; 
Supplementary Fig. 4). Since CCL2 and CCL5 have been implicated in T cell diapedesis in 
vitro23, we also considered whether Ccr5−/− and Ccr2−/− T cells were defective in their 
ability to migrate through tumor vessel walls which would not be discernible by flow 
cytometric analysis. Microscopic analysis did not reveal a disproportionate accumulation of 
adoptively transferred Ccr5−/− or Ccr2−/− T cells within tumor vessels nor a concomitant 
defect in extravasation (Fig. 4e). Overall, these data demonstrate that CCR5 and CCR2 are 
not required to cooperate with CXCR3 during T cell extravasation across tumor vessels.
Efficacy of adoptive transfer cell therapy depends on CXCR3
Evidence that CXCR3 directs homing of adoptively transferred CD8+ T cells at the tumor 
vascular interface prompted us to investigate the relationship between CXCR3 and 
antitumor immunity. In these studies we initially characterized the cytotoxic activity of WT 
and Cxcr3−/− OT-I T cells in assays where effectors have ready access to cognate targets. 
Activated Cxcr3−/− and WT OT-I cells were indistinguishable with respect to IFN-γ and 
granzyme B expression (Supplementary Fig. 5a) and exhibit equivalent specific cytotoxicity 
against cognate targets in vitro including splenocytes pulsed with SIINFEKL OVA peptide, 
B16-OVA, or OVA-expressing EG7 lymphoma (Supplementary Fig. 5b–d). Parallel results 
were obtained during in vivo cytotoxicity assays against SIINFEKL-pulsed splenocyte 
targets within the splenic compartment (Fig. 5a). These findings are in line with evidence 
that CXCR3 deficiency does not compromise localization of adoptively transferred CD8+ T 
cells within the spleen (Fig. 2b).
To test the cytotoxic activity of T cells in tumors where entry depends on CXCR3, we 
adoptively transferred a single dose of WT or Cxcr3−/− OT-I effector T cells intravenously 
into mice and monitored B16-OVA tumor progression. These studies exploited the OT-I 
TcR transgenic model system in order to dissect the therapeutic impact of chemokine-
dependent trafficking without masking chemokine contributions due to weak TCR affinity/
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avidity for tumor antigen. WT OT-I T cells caused a significant delay in tumor growth and 
prolonged survival, with cures detected in some experiments (Fig. 5b, Supplementary Fig. 
6a). Conversely, CD8+ effectors lacking Cxcr3 provided no therapeutic benefit, compared to 
untreated controls, in this stringent model where 100% of transferred cells were tumor 
(OVA)-reactive. Kinetic studies performed after adoptive transfer showed a progressive 
increase in the extent of intratumoral infiltration by WT OT-I cells, but not Cxcr3−/− OT-I 
(monitored using tracking dye or CD45 congenic mismatch), underscoring the CXCR3 
requirements for tumor immunity (Fig. 5c, Supplementary Fig. 6b). Additionally, we found 
that a high intratumoral density of WT OT-I (~10,000 OT-I per 106 total cells within 
tumors) correlated directly with tumor control in the majority of mice analyzed at 3 weeks 
post-adoptive transfer (i.e., tumors < 20 mm3 in 9/12 mice) (Fig. 5d). Conversely, WT OT-I 
were present at a low density (~50 OT-I/106 total cells in tumors) in the subgroup of mice in 
which tumors were progressing (tumors >450 mm3 in 3/12 mice). Notably, the tumor 
volume and density of WT OT-I cells detected in progressing tumors was indistinguishable 
from observations in 100% of mice treated with Cxcr3−/− OT-I that failed to reject tumors 
(Fig. 5d). These results are consistent with a prior report showing that OT-I must exceed a 
critical threshold within B16-OVA tumors for ACT immunotherapy to be successful34. 
Collectively, these data indicate that CXCR3-dependent signaling at the tumor vascular 
barrier is a critical checkpoint for the efficacy of adoptively transferred T cells.
Human effector T cells require CXCR3 for homing in melanoma
In light of the importance of CXCR3-dependent trafficking for antitumor immunity 
following adoptive T cell transfer therapy in mice, we extended our analysis of chemokine 
requirements to the trafficking of human effector T cells to human melanoma xenografts 
comprised of the M537 and M888 patient-derived melanoma cell lines20,35,36. We initially 
profiled chemokine receptor expression by human T cells that were activated and expanded 
ex vivo using clinical ACT protocols for cancer patients12,26,37. Activated PBL populations 
from normal donors (n=7) were predominantly CD3+ (>97%) with robust CXCR3 
expression on CD8+ cells (i.e., the major T cell subset), while CCR2 and CCR5 were highly 
variable among individual donors as reported previously20,37,38 (Fig. 6a, Supplementary Fig. 
7a). Chemotaxis assays in vitro further validated that activated human T cells expressed 
functional CXCR3, CCR5, and CCR2 which responded to both human and murine 
chemokines (Supplementary Fig. 7b). Since our studies with murine CD8+ effector T cells 
raised the possibility that limited CCR2 or CCR5 expression might be responsible for the 
failure to detect CCR2- or CCR5-dependent trafficking to murine melanoma, we selected 
representative donor T cell populations for adoptive transfer experiments that dually 
expressed high CXCR3/CCR2 (donor 1) or high CXCR3/CCR5 (donor 2) (Fig. 6a).
To survey the chemokine milieu available to adoptively transferred T cells in human 
melanoma xenografts, we measured both tumor-derived (human) and stromal-derived 
(murine) chemokines produced in the local tumor milieu. Differential production of tumor-
derived (human) CXCL9, CXCL10, CXCL11, CCL2, and CCL5 was observed in M537 and 
M888 xenografts in vivo (Fig. 6b) which is largely in line with previous in vitro 
observations20. However, stromal-derived murine chemokines represented the vast majority 
of local chemokine and were detected at similar levels in M537 and M888 tumor extracts 
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(Fig. 6b). Thus, M537 and M888 tumors had similar chemokine microenvironments when 
considering the combined contributions from both mouse and human chemokines, allowing 
for chemokine-dependent trafficking to be investigated in both tumor systems.
Short-term competitive homing assays were then used to examine CXCR3 contributions 
during human T cell trafficking to melanoma xenografts (Fig. 6c). CXCR3 activity was 
specifically disrupted on activated PBL prior to adoptive transfer with a blocking Ab that 
reportedly inhibits CXCR3-mediated migration in vitro39. As a second method, we 
desensitized T cells with recombinant CXCL10 to downregulate surface expression of 
CXCR340. CXCR3 inactivation by these approaches was confirmed by flow cytometry or in 
vitro chemotaxis assays (Supplementary Fig. 7c). Data in Fig. 6c demonstrate that loss of 
CXCR3 activity by Ab blockade or desensitization diminished homing of T cells from both 
donor 1 and donor 2 in M537 and M888 melanoma xenografts to the same extent as PTX-
pretreatment but did not alter localization in the spleen (Fig. 6c, Supplementary Fig. 8a). 
Homed cell populations in tumors were ≥65% CD8+ T cells, which were reflective of the 
predominantly CD8+ T cell input population (Fig. 6a). Thus, high expression of CCR2 or 
CCR5 by human effector T cells could not compensate for the absence of CXCR3. The 
CXCR3 requirement for trafficking in M537 and M888 was further validated in competitive 
homing assays using murine WT and Cxcr3−/− CD8+ effector T cells (Supplementary Fig. 
9a,b). Taken together, these data unequivocally show a non-redundant role for CXCR3 in 
trafficking of CD8+ human effector T cells in melanoma during adoptive T cell transfer 
immunotherapy.
Discussion
Successful delivery of blood-borne CD8+ effector T cells across the tumor vasculature is 
recognized as a key determinant of antitumor immunity. However, to date, there is no 
information about the hierarchy of chemokine receptors that guide tumoricidal T cells into 
the tumor microenvironment. Here, we report on the non-redundant function of CXCR3 and 
its complementary intravascular ligands during CD8+ T cell trafficking to tumor tissues. The 
requirement for CXCR3 is shared by both murine and human CD8+ effector T cells and is 
necessary for the efficacy of adoptive T cell transfer therapy in the B16-OVA tumor model. 
These findings provide mechanistic insight for observations in cancer patients that CXCR3 
expression by circulating T cells and intratumoral CXCR3 ligands are independent 
indicators of a favorable prognosis21,22. Surprisingly, CCR5 and CCR2 did not contribute to 
T cell trafficking across tumor vessels despite the presence of cognate chemokines in the 
tumor microenvironment. These findings highlight the disconnect between functional 
readouts from in vitro chemotaxis assays and in vivo trafficking. Our results corroborate 
observations that the chemotactic response to soluble chemokine does not reflect the pro-
adhesive signals delivered by immobilized chemokine on two dimensional endothelial 
surfaces41–43. Collectively, these studies reveal a unique role for CXCR3/CXCR3 ligands in 
cancer immunotherapy in vivo that could not be predicted from genomic and proteomic 
profiling of the inflammatory signature in the tumor microenvironment.
Our findings, together with recent reports23,24, suggest that the dependence of effector T 
cells on Gαi protein signaling at the vascular interface is dictated by the inflammatory 
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context, thus having broad implications outside the tumor milieu. Central to these studies 
was the discrimination of Gαi-dependent trafficking mechanisms using PTX which 
irreversibly uncouples Gαi protein signaling from chemokine receptor/ligand binding19. Our 
data establish the requirement for PTX-dependent signaling during the transition of CD8+ 
effector cells from rolling to firm arrest in tumor vessels as well as in normal vessels in the 
context of LPS-induced systemic inflammation. This requirement is in line with evidence 
that CXCR3 contributes to CD8+ T cell localization in inflamed normal skin19,44,45 as well 
as the prevailing view whereby chemokines trigger a conformational change in LFA-1, 
resulting in an ~500-fold increased affinity for ICAM-1 that stabilizes intravascular 
adhesion19,46. Intermediate chemokine receptor requirements were described during DTH 
responses in which CD8+ effectors bypass Gαi protein signaling during the firm adhesion 
step, and instead rely primarily on CCR2 during transendothelial migration23. Cardiac 
allograft rejection models represent the other end of the spectrum where extravasation of 
CD8+ effector T cells is completely independent of Gαi protein signaling24. The reasons for 
these differential chemokine requirements are unclear, but likely involve variability within 
the tissue microenvironment rather than T cell behavior since each of these disparate reports 
used activated OT-I CD8+ effector T cells. One possibility is that differences in downstream 
TLR signaling following induction of local DTH by injection of complete freund’s 
adjuvant23 (via TLR247) or by systemic LPS administration (via TLR448) account for 
distinct chemokine receptor requirements in the intravascular space49. A key difference 
between the allograft model and our studies is that Gαi-independent trafficking occurs as a 
consequence of TcR activation by transplant antigens presented by vascular endothelium or 
nearby DCs24. In contrast, results of the current study combined with our previous 
findings14 indicate that trafficking of murine T cells or normal donor-derived human CD8+ 
effectors to tumors or inflamed tissues is not antigen-restricted, which may serve to 
reinforce T cell dependence on intravascular chemokines.
Observations that CCR2 and CCR5 do not participate during CD8+ effector T cell 
trafficking into melanoma tumors raise questions about how CCR2 supports monocyte 
homing in the same intravascular chemokine environment. This could be explained, in part, 
by the recently discovered post-translational nitration of CCL2 which supports monocyte but 
not effector T cell chemotaxis in vitro38. Nitrated CCL2 is found in the tumor 
microenvironment of murine and human colon and pancreatic tumors38, presumably 
modified by nitric oxygen species derived from local protumorigenic myeloid cells. 
Furthermore, global blockade of peroxynitrite enhances T cell infiltration and decreases 
detectable nitrated CCL2 in murine tumors, although a cause-and-effect relationship for 
these observations remains to be established38. The commercial Ab used to detect 
intravascular CCL2 in our studies does not appear to recognize nitrated CCL2 in tumor 
tissues38 (Dr. Barbara Molon, personal communication), so there may still be a substantial 
pool of nitrated CCL2 on the intravascular surface which could preferentially support 
monocyte trafficking. Differential migratory responses of monocytes and T cells to nitrated 
CCL2 in vitro have been attributed to higher CCR2 surface expression on monocytes38, a 
distinction that we also observed for murine CD115+ inflammatory monocytes and CD8+ 
effectors.
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Evidence that human effector CD8+ T cells expressing high levels of CCR2 or CCR5 failed 
to utilize these receptors during trafficking to human melanoma tumors suggests that 
deficient receptor expression cannot fully account for the selective dependence of CD8+ 
effectors on CXCR3 in vivo. These results indicate that there may be cell-intrinsic properties 
that impact chemokine receptor activity in vivo, such as variations in the availability of 
molecules which regulate Gαi protein signaling downstream of receptor activation. Strong 
candidates for cell-specific negative regulation include G protein-coupled receptor kinases 
(GRK), which phosphorylate the C-terminal intracellular loop of chemokine receptors to 
prevent the association of heterotrimeric Gαβγ complexes50,51, and regulators of G protein 
signaling (RGS), which accelerate the exchange of GTP on active Gα subunits to limit signal 
duration50–52. Notably, the GRK2 isoform is elevated in activated human T cells compared 
to monocytes53,54 and is implicated in repressing both CCR2 and CCR5 signaling55,56. 
Similarly, elevated expression of RGS-1 has been reported in activated T cells compared to 
peritoneal macrophages57. Thus, it is likely that the net balance of regulatory molecules for 
Gαi signaling within cells has a substantial impact on the ability of CD8+ effectors to 
respond to intravascular CCR2 and CCR5 ligands in tumors.
Our data support a scenario whereby CXCR3-dependent delivery of blood-borne T cells at 
the vascular juncture is a critical step in therapeutic antitumor immunity. Since CXCR3, 
CCR5, and CCR2 are all associated with overall levels of T cell infiltration and positive 
outcomes in cancer patients1,20,21, it is tempting to speculate that signaling through these or 
other Gαi-linked receptors support the antitumor activity of CD8+ T cells within the 
interstitium via mechanisms independent of extravasation. For example, in vitro studies have 
shown that CXCR3 and CCR5 enhance T cell activation and proliferation58,59 while CCL2 
can increase the cytotoxicity of T cells engineered to co-express CCR2 and chimeric antigen 
receptors60. Additionally, ligand engagement of the Gαi-coupled leukotriene B4 (LTB4) 
receptor (BLT) has been linked to increased accumulation of CD8+ T cells and T cell-
mediated antitumor immunity in murine cervical cancer model61. Although not addressed in 
the current study, CXCR3 on T cells could also function outside tumor tissues by regulating 
antitumor immunity within lymphoid organs. In this regard, CXCR3 has already been 
implicated in non-tumor systems in guiding CD4+ or CD8+ T cell positioning near antigen-
loaded DCs within lymph nodes and the spleen during T cell priming and the generation of 
effector populations25,62. These observations are highly relevant to preclinical and clinical 
adoptive T cell transfer therapy in which the efficacy depends on direct cytotoxic functions 
of effector T cells within tumors as well as seeding of lymphoid organs by memory T cells 
to perpetuate long-term antitumor immunity8,12,14,18.
In summary, this report identifies the interface between CXCR3 on effector T cells and 
chemokine ligands within tumor vessels as a critical checkpoint dictating the efficacy of T 
cell-based cancer immunotherapy. The experimental strategy used here to interrogate the 
homing properties of large numbers of transferred T cells is analogous to clinical adoptive 
transfer protocols where the goal is to massively expand the tumor-specific T cell pool. As 
an example, recent studies have shown that it is technically feasible to transfer > 120 billion 
tumor-reactive T cells in a patient in a bolus injection63. Given our observations that 
CXCR3 is also required for intratumoral localization of endogenous CD8+ T cells, it is 
likely that conclusions regarding biased CXCR3 usage are also relevant to other 
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immunotherapies in which a lower frequency of tumor-reactive T cells might be generated. 
Similar CXCR3 requirements for homing of CD8+ effectors may also be operative in other 
orthotopic murine tumors such as the PyMT breast tumor model, which exhibits more 
aggressive growth after implantation in Cxcr3−/− hosts because of M2 macrophage 
polarization64.
These observations provide guidance for which chemokine receptor/chemokine pair could 
be exploited clinically to improve antitumor immunity. Our results, together with other 
published studies, demonstrate that there is universally high CXCR3 expression on ex vivo 
activated human T cells either from normal donors or cancer patients20,37. Thus, inadequate 
expression of CXCR3 does not appear to be an obstacle to adoptive T cell immunotherapy. 
In contrast, the tumor microenvironment is highly variable with respect to CXCR3 ligand 
expression1,20,21,37. This raises the possibility of using therapeutic strategies to boost 
CXCR3 ligands in the tumor locale which could be shuttled out onto the endothelial surface 
through the process of transcytosis65,66. Several approaches being studied clinically to 
promote an antitumorigenic inflammatory gene signature such as administration of TLR 
ligands (e.g., CpG or poly I:C), or IFN-α have been shown in preclinical studies to induce 
production of CXCR3 ligands by intratumoral stromal cells (fibroblasts, monocytes, or 
CD45+ leukocytes)9,15,67. Commonly used chemotherapeutic agents such as cisplatin and 
temozolomide similarly boost tumor cell expression of CXCR3 ligands in preclinical 
melanoma models, paralleling the increases in CXCL9 and CXCL10 gene expression 
detected in melanoma patient tumors after treatment with dacarbazine68. Moreover, 
intratumoral injection of recombinant CXCL10 or adenovirus encoding CXCL10 reportedly 
contributes to CD8+ T cell infiltration and tumor rejection in murine tumors69,70. Based on 
our current findings, we would predict that chemokine-targeting strategies further offers 
promise in an adjuvant setting with adoptive T cell transfer therapy, cancer vaccines, or 
checkpoint blockade inhibitors that rescue CD8+ T cell function by disrupting CTLA-4 and 
PD-1/PD-L1-mediated immune-suppressive networks8,10,11,13. It is noteworthy, in this 
regard, that elevated CXCL9 expression in patient melanoma specimens correlates with 
response to PD-L1 blockade therapy13.
Methods
Animals
Female age-matched C57BL/6 and OT-I mice on a CD45.1 background (B6.129S7-
Rag1tm1Mom Tg[TcraTcrb]1100Mjb) (8–12 weeks) were from the National Cancer 
Institute or Taconic; C57BL/6 with CD45.2 phenotype (B6.SJL-Ptprca Pepcb/BoyJ), 
Ccr5−/− (B6.129P2-Ccr5tm1Kuz/J), and Ccr2−/− mice (B6.129S4-Ccr2tm1Ifc/J) were from 
Jackson Laboratory and bred in-house along with Cxcr3−/− OT-I (on a C57BL/6/CD45.1 
background as described 29) and SCID mice (SCID C.B Igh-1b Icr Tac Prkdc scid) in the 
Roswell Park Department of Laboratory Animal Resources. Animal protocols were 
approved by the Roswell Park Cancer Institute Institutional Animal Care and Use 
Committee.
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Tumor models
B16-OVA cells and parental B16 were cultured in complete media (RPMI 1640 
supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 50 μg/ml 
streptomycin, and 50 μM β-mercaptoethanol [Invitrogen]). M537 and M888 cells were 
cultured in complete media lacking β-mercaptoethanol20,35,36. EL4 and EG7 cells were 
cultured in complete media supplemented with 1 mM sodium pyruvate, MEM non-essential 
amino acids, 25 mM HEPES (Invitrogen); media for EG7 cells contained 40 μg/mL G418 
sulfate (LifeTechnologies). Tumor cells (106) were injected subcutaneously in the flank of 
C57BL/6 mice or SCID mice as previously described14,20 and used for experimental 
analysis when tumor volume reached ~400–500 mm3 (~10–14 days or 6–8 weeks post-
implantation for murine and human melanoma, respectively) unless otherwise indicated.
T cell activation ex vivo or in vivo
Pooled murine splenocyte/lymph node populations (2 × 106 cells/ml) were activated for 2 
days in 24-well plates (Corning) coated with anti-mouse CD3 Ab (2.5 μg/ml; Cat # 550275 
clone 145–2C11; BD Biosciences) in complete media (including MEM non-essential amino 
acids, 20 mM HEPES, 1.5 mM sodium pyruvate); then diluted to 2 × 105 cells/ml, and 
expanded for 3 days with recombinant human IL-2 (12.5 ng/ml; Peprotech). Human PBMC 
were isolated from anonymous normal donor buffy-coats obtained from the Roswell Park 
blood donor center by centrifugation on a Ficoll–Hypaque gradient, washed with HBSS, and 
suspended in complete media (with 100 μg/ml streptomycin and without β-
mercaptoethanol). PBMC were activated for 2 days with anti-human CD3 Ab (2 μg/ml; Cat# 
16-0037-81 OKT3; eBiosciences) and anti-CD28 Ab, then expanded for 5 days with 
recombinant human IL-2 (300 IU/ml; Novartis). All Ab and cytokines were azide and 
endotoxin-free. DC vaccination was performed to activate CD8+ CD44+ T cells in vivo. 
Mouse bone marrow-derived DCs were generated by culturing bone marrow cells for 8 days 
in media used for murine T cell activation, supplemented with murine GM-CSF (~20 ng/ml; 
provided by Dr. Kelvin Lee, Roswell Park Cancer Institute). DCs were matured by LPS 
treatment (0.5 μg/ml) overnight, then pulsed with 5 μM SIINFEKL peptide (InvivoGen), and 
3 × 106 DCs were injected into the hind footpad; T cells were recovered from draining nodes 
(popliteal, inguinal) after 7 days. As an alternative method for in vivo activation, T cells 
were analyzed in draining nodes (inguinal) 7 days after B16-OVA tumor implantation.
Treatment with STT, LPS, or cytokine-neutralizing reagents
Mice were treated with systemic thermal therapy (STT; core temperature of 39.5 ± 0.5°C, 6 
h) and allowed to return to baseline temperature prior to homing studies as described14,27. 
LPS (1 mg/kg; Sigma) was injected i.p. 6 h prior to trafficking studies14. Neutralizing 
polyclonal anti-CXCL9 or anti-CXCL10 Ab30 (100 μg/mouse) or polyclonal isotype IgG 
control (cat# BE0091 100 μg/ mouse; BioXCell) were injected i.p. 3 h prior to competitive 
homing studies. Murine activated CD8+ T cells were pretreated with pertussis toxin (100 
ng/ml, 2.5 h; Sigma), or anti-mouse CXCR3 blocking Ab (cat# 126526 100 μg/mL, 1h; 
Biolegend). Human activated T cells were pretreated with pertussis toxin, human CXCR3 
functional blocking Ab (cat# LS-C6283-500 40 μg/ml, 30 min; LifeSpan BioSciences, 
Inc39), or human recombinant CXCL10 (500nM, 30 m; Peprotech) to desensitize CXCR340.
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Quantification of tissue and intravascular chemokines
Soluble extracts from tumor or normal skin were prepared by dissociating tissue by 
Medimachine (BD Biosciences) in the presence of protease inhibitors (CalBiochem). 
Chemokines were measured by ELISA (R&D Systems and Antigenix) or Luminex 
(Procarta) and normalized to total protein concentrations determined by Bradford analysis 
(Bio-Rad)14. Normal skin samples were from mice that received a s.c. injection of 100 μl 
sterile PBS 12 day prior to tissue harvest to mimic any needle-derived inflammation at the 
injection site. Intravascular chemokines were detected by adapting methodology used to 
identify intravascular adhesion molecules in LN28. Briefly, yellow-green fluorescent sulfate 
microspheres (Ex/Em 505/515, 1.0 μm diameter, Life Technologies) were labeled with 10 
μg/mL of Ab specific for mouse chemokines including anti-CXCL10 (cat# MAB466-500 
clone 134013), anti-CXCL9 (cat# AF392 affinity-purified polyclonal Ab), anti-CCL5 (cat# 
MAB478 clone 53405), anti-CCL2 (cat# BAF479 biotinylated affinity purified polyclonal 
goat Ab), or isotype-matched control Abs (R&D Systems)28 and injected i.v. into tumor-
bearing mice. After 1 h, tumor and pancreas were frozen in OCT (Sakura Finetek), and then 
counterstained using anti-mouse CD31 Ab (cat# 550274 clone MEC 13.3, 20 μg/ml; BD 
Biosciences) followed by an AMCA fluorochrome-conjugated goat anti-rat secondary Ab 
(cat# 112-155-003 1:50 Jackson ImmunoResearch). For consistency, fields containing a 
minimum of 1 fluorescent bead were imaged by observers blinded to sample identity, and 
the number of fluorescently beads associated with CD31+ vessels was quantified in ≥10 
fields (unit area per field, 0.34 mm2) using Image J software (http://rsb.info.nih.gov/ij) as 
described14.
Flow cytometry
Multiparameter flow cytometric analysis of murine immune cell phenotype was performed 
by staining with the following mAb: anti-CD44 (Cat# 561859 clone IM7, FITC, 1:50), anti-
CD11a (cat# 553120/cat# 558191 clone 2D7, FITC/PE, 1:100), anti-CD8a (cat# 553036 
clone 53–6.7, PerCP, 1:100; cat# 552877 clone 53-6.7, Pe-Cy7, 1:500), anti-CD11b (cat# 
561098 clone 1M/70, PE-Cy7 1:100), anti-Ly6C (cat# 560595 clone AL-21, APC, 1:100), 
anti-CCR5 (cat# 559923 clone C34-3448, PE, 1:20), anti-CD45.1 (cat# 560578 clone A20, 
PE-Cy7, 1:100), anti-CD45.2 (cat# 560695 clone 104, PE, 1:100), and CD3 (cat# 555274 
clone 17A2, FITC, 1:100) (BD Biosciences); anti-CXCR3 (cat# FAB1685A clone 220803, 
APC, 1:5), anti-CCR2 (cat# FAB5538A clone 475301, 1:5) (R&D Systems); anti-granzyme 
B (cat# 50-8898, eFluor660, 1:100), anti-IFN-γ (cat# 17-7311-82 clone XMG1.2, APC, 
1:100) (eBioscience); and anti-CD115 (cat# 130-102-554 clone AFS98, PE, 1:20; Miltenyi). 
Functional P-selectin and E-selectin ligands were detected with CD62P or CD62E-IgG 
fusion proteins, respectively (cat# 737-PS/575-ES, 1:50, R&D Systems). Human T cells 
were stained with the following Ab: Zombie UV Fixable Viability Kit (Biolegend); anti-
CD4 (cat# 563550 clone SK3, BUV395, 1:25), anti-CD3 (cat# 552851 clone SP34-2, PerCP, 
1:20), anti-CD8 (cat# 557945 clone RPA-T8, Alexa Fluor 700, 1:20), anti-CCR7 (cat# 
557648 clone 3D12, PE-Cy7, 1:20), anti-CD28 (cat# 563075 clone CD28.2, BV510, 1:20), 
anti-CD45RA (cat# 562885 clone HI100, BV421, 1:20) (BD Biosciences); anti-CCR2 (cat# 
558406 clone 48607, Alexa Fluor 647, 1:5), anti-CCR5 (cat# 556042 PE, 1:5), and anti-
CXCR3 (cat# 550967 APC, 1:5) (R&D Systems). Flow cytometric analysis was performed 
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on BD LSR2 flow cytometer (BD Biosciences); compensation and analysis were performed 
using Winlist 6.0 (Verity Software House, Inc.).
Chemotaxis assays
Chemotaxis of murine and human effector T cells was assayed in 24 well plates (5 μM pore 
size transwell insert with polycarbonate membranes; Corning). Media alone (RPMI1640 + 
1%BSA) or media containing recombinant chemokines (Peprotech) was placed at the 
bottom of triplicate wells. Murine T cell migration was assessed at 10 nM murine CXCL10, 
1 nM murine CCL2, and 10 nM murine CCL5; human T cell chemotaxis was determined at 
100 ng/mL recombinant human or murine chemokine20 unless otherwise indicated. 5 × 105 
cells were fluorescently labeled with CFSE or CTO, placed on the transwell insert, and 
incubated at 37°C for 3 h. Cells in the bottom chamber were enumerated by flow cytometry 
using Flow Count Beads (Beckman Coulter). Spontaneous migration was subtracted from all 
conditions, and data are reported either as absolute number of cells migrated or as migration 
relative to WT T cells.
In vivo homing assays
Competitive short-term (1 h) homing assays were performed by co-mixing (1:1 ratio) 2.5 × 
107 murine CD8+ T cells labeled with 5 - (and 6) - carboxyfluorescein diacetate 
succinimidyl ester (CFSE) with equal numbers of murine CD8+ T cells labeled with 5 - (and 
6) - (4 -chloromethyl) benzoyl) amino) tetramethylrhodamine (CellTracker Orange, 
Invitrogen Life Technologies) prior to i.v. adoptive transfer. In homing studies using ex vivo 
activated human T cells, ~1.5 × 107 of CFSE- or CTO-labeled cells were mixed at 
equivalent numbers prior to injection into tumor-bearing mice. Tumor and spleen were 
collected 1 h later and mechanically dissociated by Medimachine (BD Biosciences) or 
passed through a 70 μm nylon cell strainer (BD Biosciences). Ratios of fluorescent 
adoptively-transferred cells were determined by flow cytometry, and total cell numbers were 
assessed using Flow Count Beads (Beckman Coulter)14. In selected experiments 
intratumoral infiltration by OT-I cells was monitored using tracking dyes (CellVue Claret, 
Sigma Aldrich) or by congenic mismatch (CD45.1+ OT-I→CD45.2+ host) up to 3 weeks 
after transfer.
Quantification of extravasation by transferred CD8+ T cells
After short-term in vivo homing assays, organs were harvested, embedded in optimum 
cutting temperature compound (OCT, Sakura Finetek) and snap-frozen as previously 
described14. Tissue cryosections (9 μm) were incubated with the primary Ab specific for 
murine CD31 (cat# 550274 clone MEC 13.3, 20 μg/ml; BD Biosciences) followed by an 
AMCA fluorochrome-conjugated goat anti-rat secondary Ab (cat# 112-155-003, 1:50; 
Jackson ImmunoResearch) and imaged using a fluorescence microscope (Olympus Optical) 
and a SPOT RT camera (Diagnostic Instruments). In experiments in which the location of 
homed cells was determined (i.e., extravasated vs vessel-associated), all T cells not in 
contact with CD31+ endothelial cells were designated as extravasated. For consistency, 
fields containing a minimum of 1 fluorescently-labeled cell were imaged by observers 
blinded to sample identity, and labeled cells were quantified in ≥ 10 fields (unit area per 
field, 0.34 mm2).
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Inflammatory monocyte isolation and short-term homing
Tibias and femurs from either WT C57BL/6 or Ccr2−/− mice were removed sterilely, and 
bone marrow was flushed with sterile PBS. RBC were lysed with ACK lysing buffer 
(Gibco) and inflammatory monocytes were isolated on an AutoMacs machine using positive 
selection with CD115 microbeads (Miltenyi). WT CD115+ cells were labeled with CTO and 
Ccr2−/− CD115+ cells were labeled with CFSE, mixed at a 1:1 ratio, and adoptively 
transferred into B16-OVA-bearing mice. After 2 h, tumor and splenic tissues were analyzed 
for flow cytometry.
Intravital microscopy
Live imaging of tumor or normal tissues was performed as described14,27. Briefly, dorsal 
skin-flap single-sided window chambers (Research Instruments Inc.) were surgically 
implanted in C57BL/6 mice and 1 × 105 B16-OVA cells were injected into the center of the 
chamber. Mice were housed in a 30°C environmental chamber to promote wound-healing 
and the adhesive qualities of the tumor microvasculature was evaluated ~14–21 days post-
implantation. In the indicated studies, T cell interactions were also examined in non-tumor 
inflamed skin vessels. Following treatment of the mice with STT or LPS, mice were 
anesthetized (1 mg/ml xylazine and 10 mg/ml ketamine; 10 ml/kg, i.p.) and 5–10 × 107 
calcein-labeled effector WT or Cxcr3−/− OT-I T cells were injected via tail vein over the 30 
min observation period. An epi-illumination intravital microscope with a custom stage 
equipped with a warming pad and vibration dampening system (Spectra Services) was used 
to visualize the interactions between the circulating T cells and the microvasculature. Images 
were captured with an EB charge-coupled device camera (Hamamatsu Photonics) and 
recorded with a digital videocassette recorder (DSR-11; Sony) and quantified by observers 
blinded to treatment conditions. T cell interactions were quantified in unbranched vascular 
segments 100 μm in length with a diameter between 5–40 μm. The rolling fraction was the 
percentage of total cells that interacted per microvessel; sticking fraction was the percentage 
of rolling cells that subsequently adhered for ≥30 s14,27.
In vitro and in vivo cytotoxicity assays
OVA-expressing target cells (either splenocytes pulsed with 5 μg/mL SIINFEKL peptide 
[InvivoGen], B16-OVA cells, or EG7 cells) were labeled with CFSE and mixed at a 1:1 
ratio with CTO-labeled non-antigen-expressing cells (i.e., non-pulsed splenocytes, B16 
cells, or EL4 cells, respectively) and incubated in triplicate in the absence of effector T cells, 
or in the presence of a 15-fold excess of effector WT OT-I or Cxcr3−/− OT-I T cells. After 
24 h, live cells were analyzed by flow cytometry. For in vivo cytotoxicity assays, OVA-
pulsed and non-pulsed splenocytes were mixed at a 1:1 ratio (~4–5 ×106 of each population/
mouse) and transferred i.v. into naïve mice in which 3 × 107 WT or Cxcr3−/− effector OT-I 
T cells had been injected 3 h previously. 24 h later, spleens were harvested, lysed, and live 
cells were analyzed by flow cytometry. The proportion of fluorescently-labeled cells was 
plotted as CFSE+ and CFSE− cells on histograms, and the % specific cytotoxicity was 
determined by the formula [1-(% CFSE− cells/% CFSE+ cells)] × 100%.
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Tumor growth studies
WT or Cxcr3−/− OT-I effector T cells (5 × 106/mouse) were transferred i.v. into B16-OVA-
bearing mice. Experimental endpoints were reached when tumors exceeded 20 mm diameter 
or mice became moribund. Tumor volumes were calculated by determining the length of 
short (l) and long (L) diameters (volume = l2 × L/2) as described14.
Statistical analysis
All data shown are the mean ± s.e.m. and group differences were evaluated by unpaired two-
tailed Student’s t-test as described unless otherwise specified. Statistical significance of 
tumor growth was determined by two-way ANOVA for repeated measures. Survival data 
were analyzed using Kaplan-Meier log rank tests. P-values < 0.05 were considered 
significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Murine CD8+ effector T cells express an array of functional chemokine receptors 
complementary for chemokine ligands present in the tumor microenvironment
(a) Cognate chemokine ligands for CXCR3, CCR5, and CCR2 (i.e., CXCL9/CXCL10, 
CCL5, and CCL2, respectively) were quantified by ELISA in B16-OVA tumor extracts 
(tumor volume ~ 400–500 mm3) or in normal skin fom tumor-free mice. Data (mean ± 
s.e.m.) are from ≥3 independent experiments (n ≥2 mice per group). (b) Transwell assays 
were performed where fluorescently-labeled WT OT-I T cells were admixed with equivalent 
numbers of chemokine receptor-deficient effector cells and tested for migration to the 
indicated recombinant chemokines. WT and chemokine receptor-deficient cells were also 
pretreated with the global G-protein inhibitor pertussis toxin (PTX) and migration was 
quantified by flow cytometry. Background migration (absence of chemokine) was subtracted 
from all values. Data (mean ± s.e.m.) are represented as migration relative to WT and are 
from ≥3 independent experiments. (a, b) * P < 0.05; ns, not significant; unpaired two-tailed 
Student’s t-test.
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Figure 2. CXCR3 is obligatory for murine CD8+ effector T cell trafficking to melanoma in vivo
(a) Experimental scheme for short-term (1 h) competitive homing studies. The groups used 
for adoptive cell transfer (ACT) included WT OT-I cells comixed at a 1:1 ratio with WT 
OT-I cells, WT OT-I cells pretreated with PTX, Cxcr3−/− OT-I cells, or WT OT-I cells 
pretreated with α-CXCR3 blocking Ab. Fluorescent-labeled CD8+ effector T cells were 
injected i.v. into mice with established B16-OVA tumors (tumor volume ~400–500 mm3) 
and homing was evaluated after 1 h. (b) Data represent ratio of adoptively transferred T cells 
relative to WT determined by flow cytometry in tumors and spleens following competitive 
homing assays. (c) The number of WT (red) or Cxcr3−/− cells which successfully 
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extravasated into underlying interstitium was quantified in histological tumor sections 
counterstained with CD31-specific Ab (green) to demark vessels. A representative 
photomicrograph of homed WT OT-I cells is shown with an example of an extravasated cell 
indicated by a white arrow and a vessel-associated cell noted by a white arrowhead. Scale 
bar, 100 μm. (d) Ratio of adoptively transferred T cells recovered in B16-OVA tumor-
bearing mice pretreated with systemic thermal therapy (STT; 39.5 ± 0.5 °C for 6 h). PTX, 
pertussis toxin; α-CXCR3, CXCR3 blocking Ab. (b–d) All data (mean ± s.e.m.) are from ≥ 
3 independent experiments (n ≥ 2 mice per group). * P < 0.001; ns, not significant; unpaired 
two-tailed Student’s t-test.
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Figure 3. Intravascular CXCR3 ligands support stable adhesion of murine CD8+ T cells within 
tumor vessels in vivo
(a) Representative photomicrographs of intravital microscopy depicting stable interactions 
of fluorescently-tagged WT OT-I cells, WT OT-I cells pretreated with PTX, or Cxcr3−/− 
OT-I effector cells within B16-OVA tumor vessels in mice pretreated with systemic thermal 
therapy (STT; core temperature elevated to 39.5 ± 0.5 °C for 6 h). Data (mean ± s.e.m.) for 
rolling fractions and sticking fractions are from ≥3 independent experiments (n ≥2 mice per 
group). * P < 0.05. (b) Isotype- and α-CXCL10 or α-CXCL9 Ab-conjugated fluorescent 
beads (green) were injected into B16-OVA mice by tail vein. Tumor and pancreatic sections 
were counterstained with anti-CD31 Ab (blue) to identify beads associated with vascular 
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structures. Representative images from tumors containing isotype, α-CXCL9, or α-CXCL10 
Ab-conjugated beads are shown. Data (mean ± s.e.m.) are of 10 fields analyzed from paired 
mice and are from 3 independent experiments. * P < 0.001. (a, b) Scale bars, 100 μm. (c) 
Mice were treated i.p. with chemokine-neutralizing Ab 3 h prior to competitive homing 
assays using WT OT-I and Cxcr3−/− OT-I effector T cells. The ratio of WT OT-I:Cxcr3−/− 
OT-I cells within tumor and spleen was quantified by flow cytometry. Data (mean ± s.e.m.) 
are from 3 independent experiments (n = 2 mice per group). * P < 0.04, compared to isotype 
or dual Ab treatment. (a–c) Data analyzed by unpaired two-tailed Student’s t-test; ns, not 
significant.
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Figure 4. Functional cooperativity of CCR5 and CCR2 is not necessary for CXCR3-dependent 
trafficking of murine CD8+ effector T cells to tumors
(a) Isotype- and α-CCL5 or α-CCL2 Ab-conjugated fluorescent beads (green) were injected 
into B16-OVA mice by tail vein. Tumor and pancreatic sections were counterstained with 
anti-CD31 Ab (blue) to identify beads associated with vascular structures. Data (mean ± 
s.e.m.) are of 10 fields analyzed from paired mice from ≥3 independent experiments. * P < 
0.003. Scale bar, 100 μm. (b) WT effector T cells were comixed at 1:1 ratio with WT cells, 
WT cells pretreated with PTX, Cxcr3−/− cells, Ccr5−/− cells, or Ccr2−/− cells (all ex vivo 
activated cells > 88% CD8+; generated from population of pooled spleen/lymph nodes of 
mice on C57BL/6 background). Ratio of adoptively transferred T cells relative to WT in 
tumors or spleens of B16-OVA tumor-bearing mice following short-term competitive 
homing assays is shown. Data (mean ± s.e.m.) are from 3 independent experiments (n ≥ 2 
mice per group). * P < 0.001 compared to WT. (c) Percent of adoptively transferred WT and 
Ccr2−/− inflammatory CD115+ monocytes in tumors and spleens of B16-OVA tumor-
bearing mice following competitive homing assays. Data (mean ± s.e.m.) are from 3 
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independent experiments (n = 2 mice per group). * P < 0.003 compared to WT. (d) Flow 
cytometric analysis of WT CD8+ effector T cells and inflammatory CD115+ monocytes for 
surface expression of CCR2 (unfilled histograms); gray-filled histograms represent isotype 
control Ab staining. (e) Histological analysis was performed following short-term 
competitive homing assays between fluorescently-labeled WT effector CD8+ T cells and 
Ccr5−/−, and Ccr2−/− effector T cells. The proportion of homed cells which were vessel-
associated or extravasated outside CD31+ vessels are shown. Data (mean ± s.e.m.) are from 
2 independent experiments (n = 2 mice per group). (a–c, e) Data analyzed by unpaired two-
tailed Student’s t-test.
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Figure 5. Antitumor efficacy of adoptively transferred CD8+ effector T cells depends on CXCR3 
activity
(a) In vivo cytotoxicity of SIINFEKL-pulsed splenocytes. WT or Cxcr3−/− OT-I effector T 
cells were transferred into host animals prior to injection of fluorescently-labeled 
SIINFEKL-pulsed and non-pulsed targets. Spleens were analyzed for target cells by flow 
cytometry after 24 hrs. Left, representative flow plots of spleens. Right, percent specific 
lysis of SIINFEKL-pulsed targets. Data (mean ± s.e.m.) are from 2 independent experiments 
(n = 2 mice per group). * P < 0.05. (b) WT or Cxcr3−/− OT-I effector T cells were 
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adoptively transferred into mice bearing B16-OVA tumors; time of administration of 
adoptive cell transfer therapy (ACT) is denoted by the arrow. Tumor growth (left) and 
survival (right) were monitored over time; complete tumor rejection was detected in 50% of 
mice treated with WT OT-I cells. Data (mean ± s.e.m.) are representative of 4 independent 
experiments. * P < 0.001; ** P < 0.02; statistical significance of tumor growth, two-way 
ANOVA for repeated measures; survival, Kaplan-Meier log rank tests. (c, d) The extent of 
CD8+ CD44+ OT-I infiltration and (d) tumor volume were examined at various times after 
adoptive transfer using tracking dye; * P < 0.05; ns, not significant. (b–d) n ≥ 6 mice/group. 
(a, c–d) Data analyzed by unpaired two-tailed Student’s t-test.
Mikucki et al. Page 28
Nat Commun. Author manuscript; available in PMC 2015 December 25.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. Non-redundant requirement for CXCR3 during human effector T cell trafficking in 
human melanoma xenografts
(a) Chemokine receptor profile on CD8+ T cells (activated ex vivo) from PBL of 2 normal 
human donors. Gray-filled histograms represent isotype control Ab staining. (b) 
Concentration of human and murine chemokines in tumor extracts from 2 human melanoma 
xenografts (M537 and M888) was determined by Luminex and ELISA, respectively. Data 
(mean ± s.e.m.) are from 4 independent experiments (n ≥4 mice per group) for human 
chemokines and from ≥2 independent experiments (n ≥3 mice per group) for murine 
chemokines. * P < 0.05; ** P < 0.006, M537 versus M888 tumors. (c) Left, schematic for 
short-term (1 h) competitive homing studies. The groups used for adoptive cell transfer 
(ACT) included untreated (Untx) human effector T cells from donor 1 or donor 2 that were 
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comixed at a 1:1 ratio with untreated cells, PTX-pretreated cells, α-CXCR3 Ab-pretreated 
cells, or cells where CXCR3 was desensitized by exposure to recombinant CXCL10 prior to 
transfer into mice (CXCR3 dsn). Right, ratio of adoptively transferred T cells relative to 
untreated cells in tumors of M537 or M888 tumor-bearing SCID mice following short-term 
competitive homing assays is shown. PTX, pertussis toxin; α-CXCR3, CXCR3 blocking Ab. 
Data (mean ± s.e.m.) are from ≥2 independent experiments (n = 2 mice per group). * P < 
0.02; ns, not significant. (b–c) Data analyzed by unpaired two-tailed Student’s t-test.
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